新型抗癫痫药卢非酰胺的药理与临床

Pharmacology and clinical evaluation of rufinamide,a new antiepileptic drugs

卢非酰胺是一种具有三唑环结构的新型抗癫痫药,其可能的作用机制是抑制钠依赖的动作电位,FDA批准其用于4岁及以上儿童和成人伴林-戈综合征的癫痫发作的辅助治疗。现对其药理作用、药动学、药物相互作用、临床评价和安全性进行了综述。

Rufinamide is a new anti-epileptic drug with a novel structure of triazole derivatives. The suspected mechanism of action is limitation of sodium-dependent action potentials. Rufinamide has received an accelerated approval from the FDA for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in 4 years-old or older children and adults. Literature search was conducted using MEDLINE with the key word rufinamide or CGP-33011. The pharmacology, pharmacokinetics and drug interactions, clinical application and safety of rufinamide was reviewed in this paper.